- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| Mi | SciBase Expands Further Through European Market with First Sales Order to customer in Italy | 174 | PR Newswire | STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first... ► Artikel lesen | |
| 27.05. | SciBase reaches milestone with over 300,000 patients tested with Nevisense | 203 | PR Newswire | STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major... ► Artikel lesen | |
| 23.05. | SciBase publishes the Annual report for 2024 | 215 | PR Newswire | STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com.
A pdf-version of the annual report... ► Artikel lesen | |
| 14.05. | Notice to attend the annual general meeting in Scibase Holding AB (publ) | 185 | PR Newswire | STOCKHOLM, May 14, 2025 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17... ► Artikel lesen | |
| 13.05. | SciBase: Interim report | 198 | PR Newswire | STOCKHOLM, May 13, 2025 /PRNewswire/ --
January 1 - March 31, 2025
The first quarter in figures
Net sales were TSEK 8,856 (6,057), +46%. The loss after tax was TSEK 27,510... ► Artikel lesen | |
| 11.04. | SciBase launches next generation Nevisense | 228 | PR Newswire | STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce... ► Artikel lesen | |
| 25.02. | Year-end report: SciBase | 291 | PR Newswire | STOCKHOLM, Feb. 25, 2025 /PRNewswire/ --
January 1 - December 30, 2024
The fourth quarter in figures
Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17... ► Artikel lesen | |
| 25.02. | SCIBASE: Year-end report | 5 | Cision News | ||
| 21.02. | SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists | 286 | PR Newswire | STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today, that... ► Artikel lesen | |
| 30.01. | SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection | 232 | PR Newswire | STOCKHOLM, Jan. 30, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 28.01. | SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions | 275 | PR Newswire | STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 27.01. | SciBase: Recalculation of warrants of series TO 2 following rights issue | 382 | PR Newswire | STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen | |
| 23.01. | SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines | 426 | PR Newswire | STOCKHOLM, Sweden, Jan. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today... ► Artikel lesen | |
| 23.01. | SCIBASE: Nevisense (EIS) included in updated German (S1) imaging guidelines. | 2 | Cision News | ||
| 14.01. | SciBase announces final outcome of directed issue and rights issue | 428 | PR Newswire | STOCKHOLM, Jan. 14, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the final outcome of the capital raise, consisting of a rights issue of units of approximately... ► Artikel lesen | |
| 13.01. | SciBase announces outcome of directed issue and preliminary outcome of rights issue | 448 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the preliminary outcome of the capital raise, consisting of a rights issue of units... ► Artikel lesen | |
| 03.01. | SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot | 465 | PR Newswire | STOCKHOLM, Jan. 3, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that... ► Artikel lesen | |
| 27.12.24 | Today the subscription period in SciBase rights issue begins | 624 | PR Newswire | STOCKHOLM, Dec. 27, 2024 /PRNewswire/ -- Today, on December 27, 2024, is the first day of the subscription period in SciBase Holding AB's ("SciBase" or the "Company") rights issue of units... ► Artikel lesen | |
| 20.12.24 | SciBase letter from the CEO | 507 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success... ► Artikel lesen | |
| 20.12.24 | SciBase publishes prospectus | 523 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") announced on November 12, 2024 that the Board of Directors has resolved, subject to the subsequent... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 64,43 | -0,19 % | Should Investors Buy Roku Stock Instead of Netflix Stock? | ||
| SERNOVA BIOTHERAPEUTICS | 0,108 | -0,92 % | Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 90,40 | +0,67 % | Bittium Oyj: Inside Information: Bittium Corporation's Subsidiary Bittium Biosignals Ltd. and Boston Scientific Have Signed an Agreement for the Supply of Electrocardiogram Monitoring Devices | Bittium Corporation
Inside Information
Inside Information: Bittium Corporation's Subsidiary Bittium Biosignals Ltd. and Boston Scientific Have Signed an Agreement for the Supply of Electrocardiogram... ► Artikel lesen | |
| PAUL HARTMANN | 247,00 | -1,20 % | Dividendenbekanntmachungen (02.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,175 USD 0,155 EUR AKER ASA NO0010234552 26,5 NOK 2,2495 EUR ALIMAK GROUP AB SE0007158910 3 SEK 0... ► Artikel lesen | |
| SYSMEX | 14,200 | -3,40 % | Macrium Software: Macrium Partners with Sysmex America to Reduce Medical Testing Downtime and Improve Patient Care | British-based backup and recovery technology reduces labour costs by up to 75% while minimising downtime, creating a win-win for healthcare providers and patients.
MANCHESTER, England... ► Artikel lesen | |
| ADDLIFE | 17,300 | +1,94 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
| EMBECTA | 9,050 | -1,09 % | BofA cuts Embecta stock price target to $18 from $20 | ||
| ENOVIS | 27,200 | -2,86 % | Enovis Corporation: Enovis Announces First Quarter 2025 Results | Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported... ► Artikel lesen | |
| R1 RCM | 13,400 | 0,00 % | R1 RCM Inc. (RCM): Driving Strong Revenue Growth with AI-Driven Solutions and Strategic Partnerships in Healthcare | ||
| KANGJI MEDICAL | 0,845 | -2,31 % | KANGJI MEDICAL (09997): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | ||
| PULMONX | 2,620 | -3,68 % | Pulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results | REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
| SI-BONE | 16,500 | +1,23 % | SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance | First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing... ► Artikel lesen | |
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle & Wellness Ltd: Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the "Company") wishes to announce that, further to... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,625 | -2,34 % | Peijia Medical Announces 2024 Annual Results |
HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and... ► Artikel lesen | |
| KOOTH | 2,080 | +1,96 % | Kooth-Führungskräfte erhalten neue Aktienoptionen im Rahmen des Anreizplans |
SCIBASE HOLDING AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,033 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.